Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

Efficacy and Safety of Dalpiciclib Combined with Anti-HER2 Targeted Therapy and Endocrine Therapy as First-line Maintenance Treatment for Patients with Recurrent or Metastatic Hormone-Receptor-Positive, HER2-positive Breast Cancer.

Trial Details

NCT ID
NCT07610720
Phase
PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Dalpiciclib
  • Trastuzumab (Herceptin)
  • Pertuzumab
  • Pyrotinib
  • Endocrine Therapy 1
Locations (sample)
  • Guangdong, GUANGZHOU, China|42.76832,129.33635

Key Eligibility Criteria

  • Females aged 18 to 75 years with pathologically confirmed metastatic or locally advanced unresectable breast cancer.
  • Hormone receptor (HR)-positive and HER2-positive.
  • Patients with no evidence of disease progression (including CR, PR, or SD)after 4-8 cycles of first-line systemic anti-tumor therapy.
  • ECOG Performance Status: 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →